v3.22.4
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Operating expenses        
Research and development $ (14,298,925) $ (2,805,955) $ (33,830,890) $ (6,636,418)
Selling, general and administrative (6,845,045) (939,106) (23,892,011) (3,265,612)
New Warrants expenses (17,424,230) 0 (104,776,230) 0
Loss from operations (38,568,200) (3,745,061) (162,499,131) (9,902,030)
Change in fair value of derivative liabilities 285,000 0 6,127,500 0
Financial and foreign exchange gain/(loss), net 2,028,854 (14,041) 3,015,420 (57,914)
Loss before income taxes (36,254,346) (3,759,102) (153,356,211) (9,959,944)
Income tax expense (490,376) 0 (620,084) 0
Net loss $ (36,744,722) $ (3,759,102) $ (153,976,295) $ (9,959,944)
Net loss per share basic $ (0.14) $ (0.02) $ (0.62) $ (0.05)
Net loss per share diluted $ (0.14) $ (0.02) $ (0.62) $ (0.05)
Weighted-average number of shares outstanding – basic 272,040,343 220,000,000 247,010,044 220,000,000
Weighted-average number of shares outstanding – diluted 272,040,343 220,000,000 247,010,044 220,000,000

Source